Navigation Links
Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Date:6/18/2008

SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at the Jefferies 2nd Annual Healthcare Conference to be held in New York on June 24-26, 2008.

Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, will present on Wednesday, June 25, 2008 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) and will discuss the Company's strategic initiatives, product pipeline and market opportunities.

Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.halozyme.com. An archived presentation will be available on the Web site for 30 days.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), fo
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 /CNW/ - A new ... on the salaries and demographic profiles of new graduates ... the Door – Building Careers for New Grads in ... Research-Based Pharmaceutical Companies (Rx&D) and features data ... Career Focus wage subsidy program from 2013 to 2015. ...
(Date:3/30/2015)... 30, 2015 Immunocore Limited, ... to treat cancer, viral infections and autoimmune disease, ... John Bell , the Regius Professor of Medicine ... for the Strategic Coordination of Health Research, to ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) , ...
(Date:3/29/2015)...  Caris Life Sciences® today announced the presentation ... the company,s panomic, comprehensive tumor profiling service, found ... and difficult to treat gynecological cancers may inform ... improve patient outcomes. These studies were presented today ... Gynecologic Oncology (SGO) 2015 Annual Meeting on Women,s ...
(Date:3/27/2015)... Earlier this year, the Capillus272Pro™ received ... in adult men and women with androgenic alopecia (AGA) ... of IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. ... over-promise and under-deliver, FDA Clearance underscores the safety and ... more than 80 million men and women who suffer ...
Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2
... Aug. 23 Nektar,Therapeutics (Nasdaq: NKTR ) today ... and CFO. Harkness reports to Nektar President and,CEO Howard ... of the company,s,new management team. "With his strong ... to the leadership team at Nektar," Robin said. "He ...
... Inc.,(MBI) and TEC Edmonton have entered into an ... a University of Alberta,invention that can improve the ... licensing of this fundamental patent on manipulating beads ... position in,microfluidic devices," said Stevan Jovanovich, President and ...
... Important Role in Targeted Drug Development, Dosing ... European Presence, Advances PGxHealth Test Commercialization ... ... Aug. 23 Clinical Data, Inc.,(Nasdaq: CLDA ) announced today ...
Cached Biology Technology:Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer 2Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer 3Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices 2Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 2Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 3Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 4Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 5Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio 6
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/18/2015)... 2015 As mobile payments become more ... wallets and apps continue to be introduced into the market ... mobile payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), ... (NASDAQ: FB ) NXT-ID, Inc. (NASDAQ: ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... code for all sorts of biological molecules and traits. But ... similarly shape metallic structures. The team found that DNA ... gold crystals that have many applications in medicine, electronics and ... at the U. of I., the team published its surprising ...
... is an important time not only for growing but ... such as choosing foods rich in vitamins and minerals, ... studies have shown that adolescents, intake of important nutrients, ... tests, has fallen in recent years. Because nutrition and ...
... operating in the abdomen. Instruments are inserted through a ... are visualized using an endoscope. This method is less ... of "minimally invasive intervention" could also be adopted by ... patients are buildings in need of upgrading to modern ...
Cached Biology News:Oh, my stars and hexagons! DNA code shapes gold nanoparticles 2Iron, vitamins could affect physical fitness in adolescents 2Iron, vitamins could affect physical fitness in adolescents 3Minimally invasive building renovation 2Minimally invasive building renovation 3
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Recombinant Human HGF...
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Request Info...
Biology Products: